Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elici...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/ |